Faricimab-svoa (Vabysmo™)

Vabysmo (faricimab‑svoa) is covered only for FDA‑approved indications—neovascular (wet) AMD and diabetic macular edema—and non‑FDA uses are excluded. Coverage requires administration by or under an ophthalmologist, meeting the plan’s specific coverage criteria/documentation, adherence to dosing limits (6 mg intravitreal: nAMD — every ≤4 weeks for four doses then ≤every 8 weeks; DME — not more frequently than every 4 weeks), and approvals are issued for 12 months.

"Neovascular (wet) age-related macular degeneration (nAMD)"

Sign up to see full coverage criteria, indications, and limitations.